First published · Last updated
ALBI-6 – Ein neuer prognostischer Score aus ALBI und Interleukin-6 bei Patient*innen mit hepatozellulärem Karzinom unter Atezolizumab und Bevacizumab
Journal article announcing a new prognostic score (ALBI-6) combining ALBI and interleukin-6 for patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab. The supplied source data did not include further study details, results, or locations.
Categories: public-health, science-and-space
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 2/10
- Geographic reach
- 1/10
- Global importance
- 2/10
- Impact magnitude
- 2/10
- Positivity
- 6/10
- Urgency
- 1/10
Why it matters
The article presents a new prognostic score for a specific cancer treatment population.

